BridgeBio Pharma (NASDAQ:BBIO) Earns Reduce Rating from Analysts at UBS Group

Share on StockTwits

UBS Group started coverage on shares of BridgeBio Pharma (NASDAQ:BBIO) in a report published on Tuesday, The Fly reports. The firm issued a reduce rating on the stock.

A number of other research firms also recently weighed in on BBIO. Piper Jaffray Companies dropped coverage on shares of BridgeBio Pharma in a research report on Friday, October 18th. Zacks Investment Research upgraded BridgeBio Pharma from a sell rating to a hold rating in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $40.13.

NASDAQ:BBIO opened at $30.56 on Tuesday. BridgeBio Pharma has a 52 week low of $17.61 and a 52 week high of $35.67. The company has a debt-to-equity ratio of 0.14, a quick ratio of 14.00 and a current ratio of 14.00. The business’s 50-day simple moving average is $24.97.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.04. The business had revenue of $26.74 million during the quarter. Equities research analysts anticipate that BridgeBio Pharma will post -3.08 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of BridgeBio Pharma during the 2nd quarter worth approximately $476,000. Janus Henderson Group PLC acquired a new position in BridgeBio Pharma during the second quarter valued at approximately $9,331,000. TimesSquare Capital Management LLC bought a new stake in BridgeBio Pharma during the second quarter worth $4,046,000. JPMorgan Chase & Co. bought a new stake in BridgeBio Pharma during the second quarter worth $25,274,000. Finally, Monashee Investment Management LLC bought a new stake in BridgeBio Pharma during the second quarter worth $1,349,000. 83.46% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Featured Story: Closed-End Mutual Funds (CEFs)

The Fly

Analyst Recommendations for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.